TUESDAY, 8 NOVEMBER 2005

TUESDAY, 8 NOVEMBER 2005
8:00 - 9:00	Contributed Poster Presentations - Session III Viewing
9:00 - 10:30	Third Plenary Session
	The Value of Safety: A Critical Issue All Along the Development and Marketing of Pharmaceuticals Moderator: Josephine Mauskopf, PhD, Vice President, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA Speakers: Prof. Achille Caputi, Istituto Farmacologia, School of Medicine, Università di Messina, Policlinico Universitario, Messina, Italy; Prof. Bruno Stricker MD, PhD, Professor, Pharmacoepidemiology, Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands This plenary session will address the recent experiences of some important drugs which were withdrawn from the market due to AE's and to prompt consideration and comments on delays in bringing new products to market due to the need for more safety data.
10:30 - 10:45	Break
10:45 - 11:45	Issues Panels - Session II
	HEALTH POLICY/HEALTH CARE REIMBURSEMENT/COVERAGE ISSUES IP6: DO VACCINES RAISE ADDITIONAL ANALYTIC OR POLICY CHALLENGES? Moderator: Jeremy Chancellor MSc, Managing Director, Innovus Research (UK) Ltd, High Wycombe, Buckinghamshire, UK Panelists: Michael Drummond PhD, Vice President, Innovus Research (UK) Ltd, High Wycombe, UK; Joel Calmet MD, MS, Director Public Policy, Aventis Pasteur SA, Lyon, France; Elizabeth Miller OBE, BSc, MB BS, FRCPath, FFPHM, Professor, Immunisation Department, Health Protection Agency, Communicable Disease Surveillance Centre, London UK QOL/PRO METHODOLOGY ISSUES IP7: DO WE REALLY KNOW THE DIFFERENCE BETWEEN PROS AND QOL AND WHY IT'S IMPORTANT? Moderator: Olivier Chassany, Département de la Recherche Clinique et du Développement Assistance Publique Hopitaux de Paris Hôpital Saint-Louis, Paris, France Panelists: Laurie Burke RPh, MPH, Director, Study Endpoints and Label Development, Food and Drug Administration, Rockville, MD, US; Richard Willke PhD, Senior Director, Global Outcomes Research, Pfizer Inc, Bridgewater, NJ, USA; Pennifer Erickson PhD, Co-founder, O.L.G.A, State College, PA, USA HEALTH TECHNOLOGY ASSESSMENT ISSUES IP8: 'FOURTH HURDLE' SYSTEMS: HOW WELL ARE THEY USING HTA IN DECISION-MAKING? Moderator: Martin Buxton, Professor, Brunel University, Uxbridge, Middx, UK Panelists: Chris Henshall PhD, Health Technology Assessment International, University of York, York, UK; Clare McGrath BS, Director, Team Leader, Pfizer Ltd, Tadworth, Surrey, UK; John Hutton BSc, BPhil, Senior Research Leader, United BioSource Corporation, London, UK ISSUES ON USE OF HEALTH OUTCOMES RESEARCH INFORMATION BY DECISION-MAKERS IP9: THE QUALITY OF PHARMACO-ECONOMIC REIMBURSEMENT DOSSIERS Moderator: Annemarie Jansen PhD, Senior Policy Advisor, Health Care Insurance Board (CVZ), Diemen, Netherlands Panelists: Andreas Engstrom, Health Economist, Pharmaceutical Benefits Board, Solna, Sweden; Karen Lee MA, Health Economist, CCOHTA, Ottawa, Ontario, Canada; Anna Bucsics MD PhD, Main Association of Austrian Security Institutions, Vienna, Austria
11:45 - 13:30	Lunch, Exhibits & Contributed Poster Presentations - Session III
	ISPOR 10 YEARS PAST PRESIDENTS' RECOGNITION
13:30 - 14:30	Contributed Workshops III
	CLINICAL STUDY METHODOLOGY ISSUES W17: THE USE OF HISTORICAL CONTROLS TO ENABLE ACTUAL PRACTICE COMPARISONS FOR PROSPECTIVE OBSERVATIONAL STUDIES Discussion Leaders: J. Jaime Caro MD, President & Scientific Director, Caro Research Institute, Concord, MA, USA; Zeba Khan PhD, Head Health Economics & Pricing Strategy, Novartis Pharma AG Basel, Switzerland; Krista Payne MEd, HECON Study Design and Data Capture, Caro Research Institute Montreal, QC, Canada ADHERENCE/COMPLIANCE ISSUES W18: NON-COMPLIANCE WITH DRUG DOSING REGIMENS: AN UNDERESTIMATED BIAS IN DRUG TRIALS Discussion Leaders: Bernard Vrijens PhD, Chief Scientist, AARDEX Ltd, Zug CH & Vise, Belgium, and Professor, Department of Mathematical Statistics, Liege University, Liege Belgium; John Urquhart MD, Chief Scientist, Dept of Biopharmaceuitcal Sciences, AARDEX Ltd, Zug CH & Vise, Belgium, and Professor, University of California San Francisco Medical Ctr, San Francisco, CA, USA COST STUDY METHODOLOGY ISSUES W19: CALCULATING STUDY POWER FOR ECONOMIC ANALYSES ALONGSIDE CLINICAL TRIALS Discussion Leaders: Elinor CG Chumney PhD, MSc, Asst Professor, Department of Pharmacy and Clinical Science, Medical University of South Carolina, Charleston, SC, USA; Kit N Simpson DrPH, Chair and Professor, Health Administration and Policy, Medical University of South Carolina, College of Health Professions, Charleston, SC, USA HEALTH CARE COVERAGE AND REIMBURSEMENT ISSUES W20: GLOBAL PRICING AND REIMBURSEMENT STRATEGY: AN INTEGRATED ANALYTICAL FRAMEWORK Discussion Leaders: Keiron Sparrowhawk MSc, MBA, Principal, PriceSpective Ltd, Buntingford, UK; Deirdre M Mladsi BA, Global Head, Health Outcomes Strategy, RTI Health Solutions, Research Triangle Park, NC, USA; Nigel Gregson BA, Principal, PriceSpective LLC, Bluebell, PA, USA HEALTH CARE POLICY DEVELOPMENT ISSUES W21: PHARMACOECONOMICS AND MARKET ACCESS IN EUROPE: CASE STUDIES IN SCOTLAND AND THE NETHERLANDS Discussion Leaders: KH Tolley MPhil, Market Access Director, Mapi Values, Adelphi Mill, Bollington, UK; Maarten J Postma Dr, Associate Professor, Groningen University Institute for Drug Exploration, Groningen, Netherlands PATIENT REGISTRIES W22: UNDERSTANDING INTERNATIONAL REQUIREMENTS WHEN DEVELOPING AND IMPLEMENTING A GLOBAL PATIENT REGISTRY: STRATEGIES TO MAXIMIZE SUCCESS Discussion Leaders: Matthew J Gordon BA, Senior Manager, Ovation Research Group, Highland Park, IL, USA; Alison Wetherfield JD, Partner, Employment Department, McDermott Will & Emery, London, UK; Leanne Larson MPH, Senior Vice President, Patient Registries, Ovation Research Group, Highland Park, IL, USA PREFERENCE-BASED STUDIES W23: INTERNATIONAL ECONOMIC EVALUATIONS OF IMMUNISATION POLICIES: COMPARABILITY OF RESULTS AND CONCLUSIONS Discussion Leaders: Ursula M Kuehnel MSc, Head of Health Economics, Health Economics, Berna Biotech, Bern, Switzerland; Jeremy Chancellor MSc, Managing Director, Innovus Research (UK) Ltd, High Wycombe, Buckinghamshire, UK; Michael Drummond PhD, Vice President, Innovus Research (UK) Ltd, High Wycombe, UK QOL/PRO METHODOLOGY ISSUES W24: RESCUING CLINICAL TRIAL DATA FOR ECONOMIC EVALUATION Discussion Leaders: Frank De Charro, Executive Director, EuroQoL Group, Erasmus University Rotterdam, Centre for Health Policy and Law, Rotterdam, Netherlands; Xavier Badia MD, PhD, Managing Director, Health Outcomes Research Europe, Barcelona, Spain; Wolfgang Greiner MSc, Professor, Fakultaet fuer Gesundheitswissenschaften, Bielefeld University, Bielefeld, Germany; Paul Kind, Principal Investigator, Centre for Health Economics, Outcomes Research Group, University of York, York, UK
14:30 - 14:45	Break
14:45 - 15:45	Concurrent Podium Presentations - Session IV (5 podium groups with 4 presentations per group)
	Development And Application Of Methods And Concepts In Statistics For Outcomes Research MC5 ON EVALUATING COST ASSOCIATED WITH EVENT-CENSORED DATA: APPLICATION TO ALL-CAUSE GRAFT FAILURE FOLLOWING KIDNEY TRANSPLANTATION Irish WD, Wang J RTI Health Solutions, Research Triangle Park, NC, USA MC6 PERFORMANCE OF THE DMM SIMULATION MODEL IN PREDICTING REAL WORLD CHANGES IN GLYCEMIC CONTROL FOLLOWING DIAGNOSIS OF DIABETES James PW, MacAlpine R, Brennan G, Emslie-Smith A, Morris AD Ninewells Hospital and Medical School, Dundee, United Kingdom MC7 THE PHARMACOGENOMICS BIAS IN DECISION MODELS Siebert U1, Goldie SJ2, Weinstein MC3, Kuntz KM2 1 Harvard Medical School, Boston, MA, USA; 2 Harvard School of Public Health, Boston, MA, USA; 3 Harvard Center for Risk Analysis, Boston, MA, USA MC8 THE APPLICATION OF BAYESIAN METHODS TO EVALUATE THE IMPACT OF TIME-DELAY ON THE COST-EFFECTIVENESS OF PRIMARY ANGIOPLASTY FOR ACUTE MYOCARDIAL INFARCTION Palmer SJ, Asseburg C, Bravo-Vergel Y, Fenwick E, Sculpher M University of York, York, North Yorkshire, United Kingdom Preference And Utility Based Patient Reported Outcomes PR1 EVALUATION OF PREFERENCES IN GENITAL HERPES TREATMENT USING A DISCRETE CHOICE EXPERIMENT Scalone L1, Watson V2, Ryan M2, Kotsopoulos N3, Patel R4 1 Center of Pharmacoeconomics, University of Milan, Milan, Italy; 2 Health Economics Research Unit, University of Aberdeen, Aberdeen, United Kingdom; 3 Glaxo SmithKline, Brentford, United Kingdom; 4 Department of Genito Urinary Medicine, Royal South Hampshire Hospital, Southampton, United Kingdom PR2 PERCEIVED UTILITY OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B: ESTIMATES FROM UNINFECTED PERSONS IN CANADA Levy A1, Tafesse E2, Mukherjee J2, Iloeje U3, Poissant L4, Briggs A5 1 Oxford Outcomes, Vancouver, Bristis Columbia, Canada; 2 BMS, Wallingford, CT, USA; 3 Bristol-Myers Squibb Company, Wallingford, CT, USA; 4 McGill University, Montreal, QC, Canada; 5 University of Glasgow, Glasgow, United Kingdom PR3 BIPOLAR PATIENTS' STATED THERAPY PREFERENCES AND LIKELY ADHERENCE Johnson FR1, Özdemir S1, Manjunath R2, Burch SP2 1 Research Triangle Institute, Research Triangle Park, NC, USA; 2 GlaxoSmithKline, Research Triangle Park, NC, USA PR4 PATIENT PREFERENCE AND WILLINGNESS-TO-PAY FOR ANTICOAGULANT TREATMENT OPTIONS IN PATIENTS RECEIVING ORAL ANTICOAGULANT TREATMENT (OAT): A CONJOINT ANALYSIS EXERCISE Monzini M1, Carpenedo M2, Moia M2, Mantovani LG1 1 Center of Pharmacoeconomics, Milan, Italy; 2 IRCCS Maggiore Hospital and University of Milan, Milan, Italy Cost Evaluation Studies In Infectious Diseases IN1 COSTS ASSOCIATED WITH SHORTER DURATION OF ANTIBIOTIC THERAPY IN HOSPITALIZED PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA Opmeer BC, el Moussaoui R, Bossuyt PM, Speelman P, Prins JM, deBorgie CA Academic Medical Center/University of Amsterdam, AMSTERDAM, Noord-Holland, Netherlands IN2 ASSESSEMENT OF THE ADDITIONAL COST OF DROTRECOGIN ALFA (ACTIVATED) RELATIVE TO STANDARD CARE IN THE TREATMENT OF SEVERE SEPSIS IN A MULTICENTIC OBSERVATIONAL STUDY IN FRANCE Payet S1, Riou França L1, Le Lay K1, Dhainaut JF2, Vallet B3, Launois R1 1 REES France, Paris, France; 2 UNIVERSITE PARIS V, Paris, France; 3 HOPITAL CLAUDE HURIEZ, Lille, France IN3 COST-EFFECTIVENESS OF VORICONAZOLE VERSUS LIPOSOMAL AMPHOTERICIN B FOR INVASIVE ASPERGILLOSIS INFECTION IN THE UK Mesrobian X1, Loftus J2, Roberts C3, Jansen J4 1 Mapi Values USA, Boston, MA, USA; 2 Pfizer, Tadworth, Surrey, United Kingdom; 3 Pfizer Inc, New York, NY, USA; 4 MAPI VALUES, Houten, Netherlands IN4 LOWERING THE AGE THRESHOLD FOR ROUTINE INFLUENZA VACCINATION: AN ECONOMIC EVALUATION FOR FOUR EUROPEAN COUNTRIES Aballea S1, Chancellor J1, Martin M1, Wutzler P2, Carrat F3, Gasparini R4, De Juanes JR5, Drummond M1 1 Innovus Research (UK) Ltd, High Wycombe, United Kingdom; 2 Friedrich-Schiller-Universitat, Jena, Germany; 3 INSERM, Paris, France; 4 Università degli studi di Genova, Genova, Italy; 5 Hospital 12 de Octubre, Madrid, Spain Cost Evaluation Studies In Cancer CN1 COST-EFFECTIVENESS ANALYSIS OF OXALIPLATIN/5-FU/LV IN ADJUVANT TREATMENT OF STAGE III COLON CANCER IN THE UK AND GERMANY Aballea S1, Chancellor J1, Raikou M2, Drummond M1, Diel R3, Frick M4, Rosenfeld S4, Boler A5, Jourdan S6, Paulo C6, Bridgewater J7 1 Innovus Research (UK) Ltd, High Wycombe, United Kingdom; 2 London School of Economics, London, United Kingdom; 3 Heinrich-Heine-Universität, Düsseldorf, Germany; 4 Aventis Pharma Deutschland GmbH, Berlin, Germany; 5 Heron Evidence Development, Letchworth Garden City, United Kingdom; 6 Sanofi-Aventis R&D, Bagneux, France; 7 Royal Free & University College Medical School, London, United Kingdom CN2 COST-EFFECTIVENESS OF TEMOZOLOMIDE FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN THE UK Uyl-de Groot C1, Lamers LM1, Al M1, Bent van den M2, Gorlia T3, Crott R4, Mason W5, Stupp R6 1 Erasmus MC, university medical center Rotterdam, Rotterdam, Netherlands; 2 Erasmus MC, Rotterdam, Netherlands; 3 EORTC, Brussels, Belgium; 4 Centre Fédéral d'Expertise des Soins de Santé, Bruxelles, Belgium; 5 Princess Margaret Hospital, Toronto, Ontario, Canada; 6 University of Lausanne Hospitals, Lausanne, Switzerland CN3 HEALTH ECONOMIC EVALUATION BASED ON THE 5–YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL COMPARING ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT TREATMENT OF POSTMENOPAUSAL HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER Moeremans K, Annemans L IMS Health, Brussels, Belgium CN4 COST MINIMISATION ANALYSIS OF FIRST LINE POLYCHEMOTHERAPY REGIMENS IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER Launois R1, Le Lay K1, Riou França L1, Avoinet S2, Chemali N2, Vergnenegre A3 1 REES France, Paris, France; 2 Lilly, Suresnes Cedex, France; 3 CHU Dupuytren, Limoges, France
15:45 - 16:00	Break
16:00 - 17:00	Contributed Workshops IV
	ADHERENCE/COMPLIANCE ISSUES W25: CHALLENGES OF DESIGNING PROSPECTIVE AND RETROSPECTIVE COMPLIANCE STUDIES Discussion Leaders: Won Chan Lee PhD, HERQuLES, Associate Director of Health Economics, Abt Associates, Bethesda, MD, USA; Asli Memisoglu ScD, Lead Pharmacoeconomist/Outcomes Scientist, HERQuLES, Abt Associates, Lexington, MA, USA; Chris L Pashos PhD, Vice President/Executive Director, HERQuLES, Abt Associates, Lexington, MA, USA COST STUDY METHODOLOGY ISSUES W26: DRG-BASED CASE COSTS: WHY THEY ARE NOT COMPARABLE ACROSS BORDERS AND SHOULD BE USED WITH CAUTION Discussion Leaders: Judith A. O'Brien RN, BSPA, Vice President, Caro Research Institute, Concord, MA, USA HEALTH CARE COVERAGE AND REIMBURSEMENT ISSUES W27: METHODOLOGICAL CHALLENGES FOR COST-EFFECTIVENESS STUDIES FOR MEDICAL DEVICES Discussion Leaders: Mark JC Nuijten PhD, MD, MBA, Consultant, Erasmus University, Rotterdam, Netherlands HEALTH CARE POLICY DEVELOPMENT ISSUES W28: KEY ISSUES IN MARKET ACCESS: UK, SWEDEN, AND GERMANY Discussion Leaders: Pippa Anderson MSc, Director, Fourth Hurdle Consulting Limited, London, UK; Ulf Persson PhD, Research Director, IHE, The Swedish Institute for Health Economics, Lund, Sweden; Bernd Brüggenjürgen MD, MPH, Assistant Professor, Charité - Universitätsmedizin Berlin, Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie, Berlin, Germany W29: INTRODUCTION AND DIFFUSION OF INNOVATIVE INPATIENT DRUGS. COMBATING INEQUALITIES Discussion Leaders:Elly Stolk PhD , Researcher, Institute Medical Technology Assessment, Erasmus University, Rotterdam, Netherlands; Floor Nooten van PhD, Researcher, Institute for Medical Technology Assessment, Erasmus University, Rotterdam, Netherlands; Carin Uyl PhD, Director, Institute of Medical Technology Assessment, Erasmus University, Rotterdam, Netherlands PREFERENCE-BASED STUDIES W30: THE VALUE OF CONJOINT ANALYSIS IN OUTCOMES RESEARCH Discussion Leaders: JP Jansen PhD, Project Manager, Health Economics, MAPI VALUES, Houten, Netherlands; KH Tolley MPhil, Market Access Director, Mapi Values, Adelphi Mill, Bollington, UK; Elyse Trudeau PhD, Unit Director, Mapi Values, Lyon, France QOL/PRO METHODOLOGY ISSUES W31: HEALTH STATUS AND QUALITY OF LIFE ASSESSMENT FOR CRITICAL DECISION MAKERS -- CLINICIANS, ADMINISTRATORS AND HEALTH ECONOMISTS Discussion Leaders: Pennifer Erickson PhD, Co-founder, O.L.G.A, State College, PA, USA; Nancy Kline Leidy PhD, President and CEO, The MEDTAP Institute at UBC, Bethesda, MD, USA; Margaret Rothman PhD, Executive Director, HE&P, PGSM, Johnson & Johnson Pharmaceutical Services, Raritan, NJ, USA RISK ASSESSMENT/RISK MANAGEMENT ISSUES W32: RISK ADJUSTMENT IN NON-COMPETITIVE MARKETS Discussion Leaders: Kenneth D. Smith PhD, Asst Professor, Department of Health Policy, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA; Vittorio Maio PharmD, MSPH, Asst Professor, Department of Health Policy, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA; Elaine J. Yuen PhD, MBA, Research Asst Professor, Center for Research in Medical Education and Health Care, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA